Lisa Gillen

531 total citations
12 papers, 437 citations indexed

About

Lisa Gillen is a scholar working on Pharmacology, Pharmacology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Lisa Gillen has authored 12 papers receiving a total of 437 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pharmacology, 7 papers in Pharmacology and 4 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Lisa Gillen's work include Pharmacogenetics and Drug Metabolism (7 papers), Antiplatelet Therapy and Cardiovascular Diseases (4 papers) and Antibiotics Pharmacokinetics and Efficacy (4 papers). Lisa Gillen is often cited by papers focused on Pharmacogenetics and Drug Metabolism (7 papers), Antiplatelet Therapy and Cardiovascular Diseases (4 papers) and Antibiotics Pharmacokinetics and Efficacy (4 papers). Lisa Gillen collaborates with scholars based in United States, France and Jordan. Lisa Gillen's co-authors include Scott A. Waldman, Howard Greenberg, Walter W. Hauck, Maria Luisa Veronese, Barbara A. Osborne, E Péquignot, Joanne Burke, Keith Gottesdiener, Peggy Wong and Martha Huntington and has published in prestigious journals such as Clinical Pharmacology & Therapeutics, The Journal of Clinical Pharmacology and PubMed.

In The Last Decade

Lisa Gillen

12 papers receiving 419 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lisa Gillen United States 10 241 162 124 72 50 12 437
William Schary United States 10 220 0.9× 117 0.7× 89 0.7× 63 0.9× 48 1.0× 26 623
James B. Mangold United States 15 206 0.9× 154 1.0× 167 1.3× 47 0.7× 32 0.6× 26 645
Yasushi Yoshigae Japan 14 165 0.7× 96 0.6× 164 1.3× 86 1.2× 81 1.6× 27 568
Donald E. Slaughter United States 10 242 1.0× 97 0.6× 140 1.1× 44 0.6× 58 1.2× 12 583
H. Spahn Germany 17 147 0.6× 157 1.0× 78 0.6× 52 0.7× 48 1.0× 52 623
Chang‐Woo Yeo South Korea 14 245 1.0× 83 0.5× 200 1.6× 55 0.8× 67 1.3× 23 536
Eric T. Williams United States 9 129 0.5× 169 1.0× 73 0.6× 80 1.1× 26 0.5× 17 432
Catherine Z. Matthews United States 17 111 0.5× 303 1.9× 53 0.4× 44 0.6× 32 0.6× 31 615
H.F. Woods United Kingdom 8 328 1.4× 102 0.6× 130 1.0× 98 1.4× 59 1.2× 9 708
Quan Zhou China 13 189 0.8× 73 0.5× 105 0.8× 25 0.3× 37 0.7× 59 477

Countries citing papers authored by Lisa Gillen

Since Specialization
Citations

This map shows the geographic impact of Lisa Gillen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lisa Gillen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lisa Gillen more than expected).

Fields of papers citing papers by Lisa Gillen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lisa Gillen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lisa Gillen. The network helps show where Lisa Gillen may publish in the future.

Co-authorship network of co-authors of Lisa Gillen

This figure shows the co-authorship network connecting the top 25 collaborators of Lisa Gillen. A scholar is included among the top collaborators of Lisa Gillen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lisa Gillen. Lisa Gillen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Veronese, Maria Luisa, et al.. (2003). Effect of Mibefradil on CYP3A4 In Vivo. The Journal of Clinical Pharmacology. 43(10). 1091–1100. 27 indexed citations
2.
Veronese, Maria Luisa, Lisa Gillen, Joanne Burke, et al.. (2003). Exposure‐Dependent Inhibition of Intestinal and Hepatic CYP3A4 In Vivo by Grapefruit Juice. The Journal of Clinical Pharmacology. 43(8). 831–839. 112 indexed citations
3.
Greenberg, Howard, Keith Gottesdiener, Martha Huntington, et al.. (2000). A New Cyclooxygenase‐2 Inhibitor, Rofecoxib (VIOXX®), Did Not Alter the Antiplatelet Effects of Low‐Dose Aspirin in Healthy Volunteers. The Journal of Clinical Pharmacology. 40(12). 1509–1515. 35 indexed citations
4.
Greenberg, Howard, Paul Wissel, Jeffrey Barrett, et al.. (2000). Antiplatelet Effects of MK‐852, a Platelet Fibrinogen Receptor Antagonist, in Healthy Volunteers. The Journal of Clinical Pharmacology. 40(5). 496–507. 23 indexed citations
5.
Greenberg, Howard, Keith Gottesdiener, Martha Huntington, et al.. (2000). A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers.. PubMed. 40(12 Pt 2). 1509–15. 63 indexed citations
6.
Prueksaritanont, Thomayant, José M. Vega, John Rogers, et al.. (2000). Simvastatin Does Not Affect CYP3A Activity, Quantified by the Erythromycin Breath Test and Oral Midazolam Pharmacokinetics, in Healthy Male Subjects. The Journal of Clinical Pharmacology. 40(11). 1274–1279. 16 indexed citations
7.
McCrea, Jacqueline B., Thomayant Prueksaritanont, Barry J. Gertz, et al.. (1999). Concurrent Administration of the Erythromycin Breath Test (EBT) and Oral Midazolam as In Vivo Probes for CYP3A Activity. The Journal of Clinical Pharmacology. 39(12). 1212–1220. 49 indexed citations
8.
9.
McCrea, Jacqueline B., Alastair E. Cribb, Tom Rushmore, et al.. (1999). Phenotypic and genotypic investigations of a healthy volunteer deficient in the conversion of losartan to its active metabolite E-3174. Clinical Pharmacology & Therapeutics. 65(3). 348–352. 59 indexed citations
10.
Veronese, M L, et al.. (1999). Inhibition of hepatic and intestinal CYP3A4 by mibefradil measured by the erythromycin breath test (EBT) and oral midazolam pharmacokinetics (PK). Clinical Pharmacology & Therapeutics. 65(2). 131–131. 2 indexed citations
11.
Gharaibeh, Munir, Lisa Gillen, Barbara A. Osborne, Jules I. Schwartz, & Scott A. Waldman. (1998). Effect of Multiple Doses of Rifampin on the [14C N‐methyl] Erythromycin Breath Test in Healthy Male Volunteers. The Journal of Clinical Pharmacology. 38(6). 492–495. 28 indexed citations
12.
Waldman, Scott A., Barbara A. Osborne, Lisa Gillen, et al.. (1996). Pharmacokinetics and Pharmacodynamics of Tepoxalin after Single Oral Dose Administration to Healthy Volunteers. The Journal of Clinical Pharmacology. 36(5). 462–468. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by William Schary Breakdown of academic impact, for papers by James B. Mangold Breakdown of academic impact, for papers by Yasushi Yoshigae Breakdown of academic impact, for papers by Donald E. Slaughter Breakdown of academic impact, for papers by H. Spahn Breakdown of academic impact, for papers by Chang‐Woo Yeo Breakdown of academic impact, for papers by Eric T. Williams Breakdown of academic impact, for papers by Catherine Z. Matthews Breakdown of academic impact, for papers by H.F. Woods Breakdown of academic impact, for papers by Quan Zhou
Rankless by CCL
2026